Ozempic went from a niche diabetes drug to a cultural phenomenon in just a few years, and the reasons go beyond celebrity gossip or social media trends. A combination of genuine medical breakthroughs, expanding off-label use, viral visibility, and a drug that works on the brain in ways scientists are still mapping out has created a perfect storm of demand. An estimated 6.9 million adults with diabetes alone were using GLP-1 injectable medications in 2024, and that number doesn’t capture the millions more using them primarily for weight loss.
It Works on the Brain, Not Just the Gut
Semaglutide, the active ingredient in Ozempic, mimics a hormone called GLP-1 that your body naturally produces after eating. But the drug does far more than slow digestion. Receptors for this hormone are scattered throughout the brain, in regions that control hunger, fullness, reward, and decision-making around food. When the drug activates neurons in the brainstem, it essentially floods the brain with a stop-eating signal, shutting down the drive to keep consuming.
What makes this especially compelling is how semaglutide affects the reward system. In animal studies, dopamine normally spikes after a sweet meal in much the same way it spikes in response to addictive substances. With a GLP-1 drug on board, that dopamine peak is largely squelched. The food still tastes fine, but the intense wanting, the pull toward it, fades. This is what many users describe as the disappearance of “food noise,” that constant background chatter of thinking about what to eat next. For people who have spent years battling intrusive food thoughts, this effect feels life-changing in a way that previous weight-loss drugs never achieved.
Off-Label Use Exploded Quickly
Ozempic was approved in 2017 specifically for type 2 diabetes. But doctors noticed their patients were losing significant weight, and word spread fast. Data from the Health Care Cost Institute shows how rapidly the shift happened: in 2018, 92% of new Ozempic users had a diabetes diagnosis. By 2021, that had fallen to 77%. Over the same period, the share of new users who had an obesity diagnosis but no diabetes or prediabetes tripled, going from about 4% to 13%.
Those numbers only capture what’s visible in insurance claims. They don’t account for people paying out of pocket, using telehealth startups, or obtaining compounded versions. The real volume of weight-loss use is almost certainly higher. Novo Nordisk eventually channeled this demand into Wegovy, the same molecule at a higher dose approved specifically for weight management, but by then Ozempic had already become the shorthand for the entire category.
Social Media Turned It Into a Household Name
TikTok was the accelerant. A 2023 study analyzing videos posted under the hashtag #Ozempic found they had been viewed roughly 70 million times. The vast majority of these videos were posted by everyday users, not doctors or pharmacists. Over one-third of the videos actively encouraged others to try the drug or portrayed it in a positive light, racking up more than 31 million views on their own. The most common theme, appearing in the majority of videos, was weight loss.
This created a feedback loop. People saw transformation videos, asked their doctors about the drug, started their own courses, and then posted their own results. Celebrity speculation added fuel. When tabloids began guessing which actors and public figures were using semaglutide, it removed the stigma for many people and reframed the drug as something aspirational rather than medical. The conversation shifted from “a diabetes treatment” to “the thing everyone’s on.”
New Medical Uses Keep Expanding Demand
Weight loss alone would have been enough to drive demand, but semaglutide keeps showing benefits that go well beyond the scale. The SELECT trial, one of the largest cardiovascular studies of the drug, found a 20% reduction in major adverse cardiovascular events (heart attacks, strokes, and cardiovascular death) among patients who had heart disease and elevated BMI but did not have diabetes. That’s a striking result for a drug originally designed to manage blood sugar.
Researchers are also investigating semaglutide’s effects on kidney disease, sleep apnea, liver disease, and even addiction. Each new positive finding widens the pool of people who might benefit and gives doctors more reasons to prescribe it. The drug is no longer a single-purpose medication. It’s becoming something closer to a platform, with potential applications that keep multiplying.
The Side Effects Are Real but Manageable for Most
Semaglutide is not a free ride. Gastrointestinal side effects are common, especially in the early weeks. In clinical studies, nausea affected anywhere from 37% to 53% of people taking the drug, compared to about 22% on placebo. Vomiting occurred in roughly 30% of users in one study, versus under 5% on placebo. Diarrhea affected between 9% and 35% depending on the study.
For most people, these symptoms ease as the body adjusts and the dose gradually increases. But they’re unpleasant enough that a meaningful number of users stop the drug or stay at lower doses. There are also open questions about what happens when someone stops taking semaglutide, since studies consistently show weight regain after discontinuation. This positions the drug less as a one-time fix and more as a long-term or even lifelong commitment for many users.
Cost Creates a Two-Tier System
Ozempic’s list price from the manufacturer is $499 per month. With insurance, the cost can drop dramatically, but coverage varies widely. Some plans cover it readily for diabetes and deny it for weight loss. Others don’t cover it at all. This inconsistency has created a gap: people with good insurance or disposable income can access the drug easily, while others face significant financial barriers.
The demand-supply mismatch got bad enough that both semaglutide and tirzepatide (the active ingredient in Mounjaro) landed on the FDA’s official drug shortage list. That shortage opened the door for compounding pharmacies to produce their own versions at lower prices, creating a booming secondary market. As supply has stabilized, the FDA has tightened rules on compounders, limiting most to filling four or fewer prescriptions per month of drugs that are essentially copies of commercially available products. The legal and regulatory landscape remains in flux, but the appetite for cheaper alternatives isn’t going anywhere.
Why It Feels Like “Everyone”
The perception that everyone is on Ozempic outpaces the reality, but it’s grounded in something real. The drug works noticeably. People lose weight visibly. And unlike previous weight-loss medications, which carried stigma or serious safety concerns, semaglutide arrived with strong clinical data and cardiovascular benefits that gave it mainstream medical credibility.
Combine a drug that genuinely changes how your brain relates to food, a social media ecosystem that amplifies personal testimonials, expanding medical indications, and a cultural moment where the conversation around obesity is shifting from willpower to biology, and you get exactly what we’re seeing: a medication that crossed over from clinical tool to cultural phenomenon faster than almost anything in modern pharmaceutical history.